Meyka Pro banner
Izotropic Corporation

Izotropic Corporation Fundamental Analysis (CNQ: IZO.CN)

IZO.CN●CNQ
HealthcareMedical - Diagnostics & Research
$0.13
$0.010(8.70%)
Canadian Market opens in 14h 21m

Izotropic Corporation Fundamental Analysis (CNQ: IZO.CN)

Izotropic Corporation (CNQ: IZO.CN) shows moderate financial fundamentals with a PE ratio of -3.69, profit margin of 0.00%, and ROE of 40.45%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

ROE40.45%
PEG Ratio-4.56

Areas of Concern

Operating Margin0.00%
Cash Position0.66%
Current Ratio0.02
We analyze IZO.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 56.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C
56.6/100

We analyze IZO.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

IZO.CN struggles to generate sufficient returns from assets.

ROA > 10%
-8.49%

Valuation Score

Excellent

IZO.CN trades at attractive valuation levels.

PE < 25
-3.69
PEG Ratio < 2
-4.56

Growth Score

Weak

IZO.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

IZO.CN shows balanced financial health with some risks.

Debt/Equity < 1
-0.52
Current Ratio > 1
0.02

Profitability Score

Weak

IZO.CN struggles to sustain strong margins.

ROE > 15%
40.45%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is IZO.CN Expensive or Cheap?

P/E Ratio

IZO.CN trades at -3.69 times earnings. This suggests potential undervaluation.

-3.69

PEG Ratio

When adjusting for growth, IZO.CN's PEG of -4.56 indicates potential undervaluation.

-4.56

Price to Book

The market values Izotropic Corporation at -1.42 times its book value. This may indicate undervaluation.

-1.42

EV/EBITDA

Enterprise value stands at -3.33 times EBITDA. This is generally considered low.

-3.33

How Well Does IZO.CN Make Money?

Net Profit Margin

For every $100 in sales, Izotropic Corporation keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $40.45 in profit for every $100 of shareholder equity.

40.45%

ROA

Izotropic Corporation generates $-8.49 in profit for every $100 in assets, demonstrating efficient asset deployment.

-8.49%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.01 in free cash annually.

$-0.01

FCF Yield

IZO.CN converts -8.40% of its market value into free cash.

-8.40%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.69

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-4.56

vs 25 benchmark

P/B Ratio

Price to book value ratio

-1.42

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.52

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.02

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.40

vs 25 benchmark

ROA

Return on assets percentage

-8.49

vs 25 benchmark

ROCE

Return on capital employed

0.24

vs 25 benchmark

How IZO.CN Stacks Against Its Sector Peers

MetricIZO.CN ValueSector AveragePerformance
P/E Ratio-3.6931.44 Better (Cheaper)
ROE40.45%607.00% Weak
Net Margin0.00%5423.00% Weak
Debt/Equity-0.52-0.05 (disorted) Distorted
Current Ratio0.025.97 Weak Liquidity
ROA-848.96%-152.00% (disorted) Weak

IZO.CN outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Izotropic Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ